The BRSK2 Knockout HAP1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the BRSK2 gene in the HAP1 human cell line. This product provides a genetically heterogeneous pool of knockout cells, enabling robust loss-of-function studies without the clonal selection bottlenecks associated with single-cell-derived lines. The knockout population is generated using CRISPR/Cas9-mediated gene disruption, leading to functional inactivation of BRSK2 across the cell pool. This format is particularly advantageous for high-throughput screening applications and for experimental designs that require representation of diverse mutational outcomes. As a research tool, these polyclonal knockout cells facilitate investigation of BRSK2-dependent signaling pathways and cellular processes in a near-haploid genetic background.
HAP1 is a near-haploid human cell line originally derived from the chronic myeloid leukemia cell line KBM-7. The haploid karyotype of HAP1 cells simplifies genetic manipulation and phenotypic analysis, as only one allele needs to be disrupted to achieve a null phenotype. This characteristic makes HAP1 an ideal host for CRISPR-based knockout modeling, eliminating the complexity of diploid genomes and reducing off-target effects. HAP1 cells retain many features of the parental leukemic lineage but are amenable to studies beyond cancer biology, including neuronal signaling and cell cycle regulation. Their rapid growth and ease of culture further support scalable functional genomics workflows.
BRSK2 encodes a serine/threonine kinase that functions downstream of the tumor suppressor kinase LKB1 (STK11). Upon energy stress, LKB1, in complex with STRAD and MO25, phosphorylates and activates BRSK2, which then phosphorylates key substrates to coordinate neuronal polarization and cell cycle progression. In neurons, BRSK2 phosphorylates the microtubule-associated protein Tau (MAPT) to regulate axon specification and polarity establishment. In proliferating cells, BRSK2 phosphorylates the cell cycle regulators WEE1 and CDC25, thereby controlling G2/M transition. Additionally, BRSK2 interacts with 14-3-3 proteins and is implicated in the AMPK and mTOR signaling pathways, linking metabolic status to cellular growth and autophagy. Its activation by CaMKK2 further integrates calcium signaling with these processes.
In the context of HAP1 cells, BRSK2 disruption provides a clean genetic model for dissecting LKB1-BRSK2 signaling independent of confounding paralogues or adaptive compensation typical of diploid cells. The near-haploid background ensures that knockout phenotypes are direct and unattenuated, thereby enhancing the sensitivity of cell cycle analyses, kinase activity measurements, and drug response profiling. The BRSK2 knockout polyclonal pool is particularly suited for phenotypic screens aimed at identifying synthetic lethal interactions or for validating BRSK2 as a therapeutic target in cancers exhibiting aberrant cell cycle control. Moreover, while HAP1 is not of neuronal origin, its utility in haploid genetic screening permits systematic investigation of BRSK2-dependent pathways relevant to neurodevelopmental disorders, complementing studies in neuronal cell models.
Researchers can employ these knockout cells in a variety of experimental workflows, including western blotting and phospho-specific antibody detection to monitor downstream signaling, immunofluorescence to assess subcellular localization of BRSK2 targets such as ??-tubulin at the centrosome, and flow cytometry for precise cell cycle profiling. RT-qPCR and kinase activity assays further enable quantification of transcriptional and functional consequences of BRSK2 loss. The polyclonal format is especially valuable for drug target validation in neurological disorders and cancer, as it mitigates clonal artifacts. For detailed technical specifications, researchers are encouraged to contact Ascent Research and discuss how this BRSK2 knockout tool can be integrated into their gene function studies, screening campaigns, or translational research programs.
